Fecal microbiota transplantation: facts and controversies

Els van Nood, Peter Speelman, Max Nieuwdorp, Josbert Keller

Research output: Contribution to journalReview articleAcademicpeer-review

69 Citations (Scopus)
2 Downloads (Pure)

Abstract

PURPOSE OF REVIEW: To review the current evidence on fecal microbiota transplantations (FMTs) for recurrent Clostridium difficile infections (CDIs), metabolic syndrome and inflammatory bowel disease.

RECENT FINDINGS: Recently, a randomized trial confirmed the efficacy of this treatment strategy in patients with recurrent CDI. For other disorders, evidence is still limited. To date, studies have been performed to try and influence the course of metabolic syndrome and inflammatory bowel disease.

SUMMARY: There is increasing interest in the role of altered microbiota in the development of a myriad of diseases. Together with new insights comes an interest in influencing this altered microbiota as a potential target for therapy. FMTs are effective against recurrent CDI, a disorder caused by disruption of the normal microbiota. Restoration of intestinal flora and thereby restoration of colonization resistance is thought to be the mechanism responsible for cure. With the developments in FMT and the extension of this treatment modality to both intestinal and extra-intestinal diseases, a new field of targeted therapy awaits. The ultimate goal is the development of powerful probiotic regimens that can replace FMT. Currently, FMT should only be given in a strict experimental setting for other conditions than CDI.

Original languageEnglish
Pages (from-to)34-9
Number of pages6
JournalCurrent Opinion in Gastroenterology
Volume30
Issue number1
DOIs
Publication statusPublished - Jan 2014
Externally publishedYes

Fingerprint

Dive into the research topics of 'Fecal microbiota transplantation: facts and controversies'. Together they form a unique fingerprint.

Cite this